High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors
Open Access
- 10 May 2023
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (14) , 2523-2535
Abstract
PURPOSE: To investigate the prevalence of and clinical factors associated with high-grade serous carcinoma (HGSC) at risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic BRCA1/2-pathogenic variant (PV) carriers. PATIENTS AND METHODS: We included BRCA1/2-PV carriers who underwent RRSO between 1995 and 2018 from the Hereditary Breast and Ovarian cancer in the Netherlands study. All pathology reports were screened, and histopathology reviews were performed for RRSO specimens with epithelial abnormalities or where HGSC developed after normal RRSO. We then compared clinical characteristics, including parity and oral contraceptive pill (OCP) use, for women with and without HGSC at RRSO. RESULTS: Of the 2,557 included women, 1,624 had BRCA1, 930 had BRCA2, and three had both BRCA1/2-PV. The median age at RRSO was 43.0 years (range: 25.3-73.8) for BRCA1-PV and 46.8 years (27.6-77.9) for BRCA2-PV carriers. Histopathologic review confirmed 28 of 29 HGSCs and two further HGSCs from among 20 apparently normal RRSO specimens. Thus, 24 (1.5%) BRCA1-PV and 6 (0.6%) BRCA2-PV carriers had HGSC at RRSO, with the fallopian tube identified as the primary site in 73%. The prevalence of HGSC in women who underwent RRSO at the recommended age was 0.4%. Among BRCA1/2-PV carriers, older age at RRSO increased the risk of HGSC and long-term OCP use was protective. CONCLUSION: We detected HGSC in 1.5% ( BRCA1-PV) and 0.6% ( BRCA2-PV) of RRSO specimens from asymptomatic BRCA1/2-PV carriers. Consistent with the fallopian tube hypothesis, we found most lesions in the fallopian tube. Our results highlight the importance of timely RRSO with total removal and assessment of the fallopian tubes and show the protective effects of long-term OCP.Keywords
This publication has 41 references indexed in Scilit:
- Risk-Reducing Salpingo-Oophorectomy (RRSO) in BRCA Mutation CarriersInternational Journal of Gynecological Cancer, 2011
- Microscopic and Early-Stage Ovarian Cancers in BRCA1/2 Mutation Carriers: Building a Model for Early BRCA-Associated TumorigenesisCancer Prevention Research, 2011
- High Risk for Ovarian Cancer in a Prospective Series Is Restricted to BRCA1/2 Mutation CarriersClinical Cancer Research, 2008
- Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?International Journal of Cancer, 2008
- Meta-Analysis of BRCA1 and BRCA2 PenetranceJournal of Clinical Oncology, 2007
- No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studyBritish Journal of Cancer, 2007
- Lessons from BRCA: The Tubal Fimbria Emerges as an Origin for Pelvic Serous CancerClinical Medicine & Research, 2007
- Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high‐grade carcinomas support different pathogenetic pathwaysThe Journal of Pathology, 2005
- Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancerThe Journal of Pathology, 2001
- Occult Carcinoma in Prophylactic Oophorectomy SpecimensAmerican Journal of Surgical Pathology, 2001